Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Cardiovascular Genetics
Search: search_blue_button Advanced Search
Circulation: Cardiovascular Genetics. 2008;1:133-140
Published online before print December 9, 2008, doi: 10.1161/CIRCGENETICS.108.797704
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
1/2/133    most recent
CIRCGENETICS.108.797704v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rutsch, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rutsch, F.
Related Collections
Right arrow Peripheral vascular disease
Right arrow Pediatric and congenital heart disease, including cardiovascular surgery
Right arrow Clinical genetics

Original Articles

Hypophosphatemia, Hyperphosphaturia, and Bisphosphonate Treatment Are Associated With Survival Beyond Infancy in Generalized Arterial Calcification of Infancy

Frank Rutsch, MD; Petra Böyer, MS; Yvonne Nitschke, MS; Nico Ruf, PhD; Bettina Lorenz-Depierieux, PhD; Tanja Wittkampf, PhD; Gabriele Weissen-Plenz, PhD; Rudolf-Josef Fischer, MD, PhD; Zulf Mughal, MBChB, FRCPCH, DCH; John W. Gregory, MD; Justin H. Davies, MD, FRCPCH, MRCP; Chantal Loirat, MD; Tim M. Strom, PhD; Dirk Schnabel, MD; Peter Nürnberg, PhD; Robert Terkeltaub, MD and the GACI Study Group

From the Department of General Pediatrics (F.R., P.B., Y.N., T.W.), University Children’s Hospital, Münster, Germany; Laboratory of Developmental Genetics and Imprinting (N.R.), The Babraham Institute, Cambridge, United Kingdom; Institute of Human Genetics (B.L.-D., T.M.S.), Helmholtz Zentrum München, Munich, Germany; Institute of Human Genetics (B.L.-D., T.M.S.), Klinikum rechts der Isar, Technical University, Munich, Germany; Department of Cardiothoracic Surgery (G.W.-P.), University Hospital, Münster, Germany; Department of Medical Informatics and Biomathematics (R.-J.F.), Münster University Hospital, Münster, Germany; Department of Paediatrics (Z.M.), Saint Mary’s Hospital for Women and Children, Manchester, United Kingdom; Department of Pediatric Endocrinology (J.W.G.), Wales School of Medicine, Cardiff University, Cardiff, United Kingdom; Department of Pediatric Endocrinology (J.H.D.), Southampton University Hospital, Southampton, United Kingdom; Department of Pediatric Nephrology (C.L.), Hôpital Robert Debré, Paris, France; Pediatric Endocrinology (D.S.), Otto Heubner Center, Charité, Berlin, Germany; Cologne Center for Genomics (P.N.), University of Cologne, Germany; and Department of Rheumatology Allergy/Immunology (R.T.), VA Medical Center, UCSD, San Diego, Calif.

Correspondence to Dr Frank Rutsch, Klinik und Poliklinik für Kinder-und Jugendmedizin, Universitätsklinikum Münster, Albert-Schweitzer Strasse 33, D-48149 Münster, Germany. E-mail rutschf{at}mednet.uni-muenster.de

Received June 9, 2008; accepted October 15, 2008.

Background— Generalized arterial calcification of infancy has been reported to be frequently lethal, and the efficiency of any therapy, including bisphosphonates, is unknown. A phosphate-poor diet markedly increases survival of NPP1 null mice, a model of generalized arterial calcification of infancy.

Methods and Results— We performed a multicenter genetic study and retrospective observational analysis of 55 subjects affected by generalized arterial calcification of infancy to identify prognostic factors. Nineteen (34%) patients survived the critical period of infancy. In all 8 surviving patients tested, hypophosphatemia due to reduced renal tubular phosphate reabsorption developed during childhood. Eleven of 17 (65%) patients treated with bisphosphonates survived. Of 26 patients who survived their first day of life and were not treated with bisphosphonates only 8 (31%) patients survived beyond infancy. Forty different homozygous or compound heterozygous mutations, including 16 novel mutations in ENPP1, were found in 41 (75%) of the 55 patients. Twenty-nine (71%) of these 41 patients died in infancy (median, 30 days). Seven of the 14 (50%) patients without ENPP1 mutations died in infancy (median, 9 days). When present on both alleles, the mutation p.P305T was associated with death in infancy in all 5 cases; otherwise, no clear genotype-phenotype correlation was seen.

Conclusion— ENPP1 coding region mutations are associated with generalized arterial calcification of infancy in {approx}75% of subjects. Except for the p.P305T mutation, which was universally lethal when present on both alleles, the identified ENPP1 mutations per se have no discernable effect on survival. However, survival seems to be associated with hypophosphatemia linked with hyperphosphaturia and also with bisphosphonate treatment.

Key Words: genetics • mortality • pediatrics • prognosis • survival

The online-only Data Supplement is available at http://circgenetics.ahajournals.org/cgi/content/full/CIRCGENETICS.108.797704/DC1.